Stoke Therapeutics
STOK
198 hedge funds and large institutions have $2.31B invested in Stoke Therapeutics in 2026 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 80 increasing their positions, 52 reducing their positions, and 27 closing their positions.
63% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 27
54% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 52
9% more capital invested
Capital invested by funds: $2.13B → $2.31B (+$189M)
8% more funds holding
Funds holding: 183 → 198 (+15)
2.95% more ownership
Funds ownership: 117.28% → 120.23% (+3%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
57% less call options, than puts
Call options by funds: $3.7M | Put options by funds: $8.68M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$77.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$51.2M |
| 3 |
TCA
Troluce Capital Advisors
Dorado,
Puerto Rico
|
+$21.4M |
| 4 |
Millennium Management
New York
|
+$15.5M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$38.8M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$21M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$10.5M |
| 4 |
Goldman Sachs
New York
|
-$10.2M |
| 5 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$8.26M |
STOK Hedge Fund Activity: Q1 2026 in Review
198 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q1 2026, worth a combined $2.31B — up 8.9% from $2.13B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new STOK positions and 27 closed out — a net gain of 17 holders — while 80 added to existing stakes and 52 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $77.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $38.8M sold.
- 198 institutional investors held Stoke Therapeutics (STOK) as of Q1 2026, up from 183 in Q4 2025.
- Funds reported $2.31B of Stoke Therapeutics stock for Q1 2026, up 8.9% quarter-over-quarter.
- 44 funds opened new Stoke Therapeutics positions in Q1 2026 and 27 closed out, a net change of +17 holders.
- The largest Stoke Therapeutics buyer in Q1 2026 was Wellington Management Group, an estimated $77.4M added.
- The largest Stoke Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $38.8M sold.
Based on aggregated 13F filings for Q1 2026.